医学
二甲双胍
蛋白激酶A
动作(物理)
药理学
内科学
激酶
内分泌学
糖尿病
细胞生物学
量子力学
生物
物理
作者
J. G. Boyle,Ian P. Salt,Gerry McKay
标识
DOI:10.1111/j.1464-5491.2010.03098.x
摘要
Diabet. Med. 27, 1097–1106 (2010) Abstract Clinical studies in Type 2 diabetes mellitus have shown that the effects of metformin go beyond improving HbA 1c and include reductions in cardiovascular endpoints. Metformin therapy has been widely used in the treatment of Type 2 diabetes for many years, yet the precise mode of action remains uncertain. It has recently been proposed that metformin‐mediated stimulation of hepatic AMP‐activated protein kinase (AMPK) underlies the hypoglycaemic effects of metformin. AMPK is a heterotrimeric enzyme that is expressed in many tissues and plays a central role in the regulation of energy homoeostasis. Furthermore, there is increasing evidence that AMPK is implicated in the pathophysiology of cardiovascular and metabolic diseases. The generation of more specific and potent activators of AMPK, however, could have additional metabolic and vascular benefits for patients with Type 2 diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI